XML 55 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value of Financial Instruments - Change in Fair Value (Details) - Contingent Consideration - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Pelican Therapeutics, Inc.    
Change in fair value    
Balance at the beginning $ 3,342,515 $ 2,912,515
Change in fair value (3,342,515) 430,000
Balance at end   $ 3,342,515
Elusys Therapeutics    
Change in fair value    
Acquisition of Elusys 39,853,685  
Payment of receivable consideration (20,784,571)  
Payment of inventory consideration (4,735,000)  
Payment of deferred cash consideration (2,000,000)  
Change in fair value (109,500)  
Balance at end $ 12,224,614